New company, new name: Actavis to rebrand as Allergan post-buyout

Call it "Actavis 2.0."

By Nicole Gray • Feb. 20, 2015

UPDATE: Bayer HealthCare chief Brandicourt named Sanofi's next CEO

Four months after the ouster of former Sanofi CEO Chris Viehbacher, the company has decided to hire a pharma veteran. But just how much power will Brandicourt have?

By Nicole Gray , Sy Mukherjee • Feb. 19, 2015

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Why so little uptake of preventive Truvada in the at-risk gay community?

Almost 50,000 people are still becoming HIV-infected each year—and 60% of them are gay men.

By Nicole Gray • Feb. 19, 2015

Team of rivals? Scientist nominated for AZ board has history of dinging pharma

AstraZeneca (AZ) has chosen Dr. Cori Bargmann, a well-respected researcher at Rockefeller University in New York, to stand for election in April and for a seat on its science committee.

By Nicole Gray • Feb. 19, 2015

Gilead's Harvoni supplants Sovaldi as top-selling launch drug

Harvoni's already outpaced Sovaldi sales over a comparable period of time.

By Nicole Gray • Feb. 19, 2015

The more, the merrier? Endo also pursuing Salix Pharma bid

On top of Valeant and Shire.

By Nicole Gray • Feb. 18, 2015

CVS fires controversial warning shot in opening salvo of PCSK9 price wars

CVS' estimates of PCSK9 costs are raising some eyebrows.

By Nicole Gray • Feb. 18, 2015

Profits fall for India's largest drug maker

Sun Pharma's Q3 earnings fell from roughly $250 million in 2013 to $229.6 million in 2014, due in large part to a decline in U.S. sales and the transaction costs of dealing with regulators. 

By Nicole Gray • Feb. 17, 2015

Can AZ finally solidify a deal for its anti-infectives unit?

For more than a year, AstraZeneca has been shopping a partnership deal for its anti-infectives unit. But there don't seem to be any takers—and the clock is ticking.

By Nicole Gray • Feb. 17, 2015

GSK replaces US pharma ops head Connelly amid struggles

In the midst of slumping share prices and poor performance in the U.S. market, GSK is trying to shore up performance by promoting Jack Bailey to head of US pharmaceutical operations.

By Nicole Gray • Feb. 17, 2015

How ViiV Healthcare became a pharma favorite for patient groups

An extensive new international patient-group survey about pharma companies' corporate reputations places patient-centricity front and center. ViiV Healthcare talked to us about what keeps them on top.

By Nicole Gray • Feb. 13, 2015

Shire raises 2015 forecast on NPS acquisition

After striking a $5.2 billion deal for NJ-based NPS Pharma last month, Shire, which is based in Ireland, is forecasting growth in the 5% to 9% range.

By Nicole Gray • Feb. 12, 2015

UPDATED: Sanofi to chop 100 US jobs in oncology R&D, Genzyme reorg

The news comes on the heels of the company's announcement earlier this week that it is replacing a third of its diabetes sales managers to bolster that franchise. 

By Sy Mukherjee • Feb. 11, 2015

Citi analyst: Humira biosims will hurt AbbVie sales more than you think

Citi analyst Andrew Baum thinks biosimilars will eat into 36% of AbbVie's U.S. Humira market share after just three years of availability.

By Sy Mukherjee • Feb. 11, 2015

Patient groups rank ViiV Healthcare #1 in corporate reputation survey, again

In a survey of 1,150 patient groups from 58 countries, patients ranked the Pfizer/GSK HIV collaborative number one across the board—and Mylan Labs at #37.

By Nicole Gray • Feb. 11, 2015

Merck fights back after BC Health Ministry drops diabetes drug

Merck fielded a survey in which 85% of doctors said that drug substitution on economic grounds is bad for patients in light of the agency's decision to drop a diabetes med.

By Nicole Gray • Feb. 10, 2015

ICYMI: Sanofi undertakes major sales reorg of US diabetes business

Sanofi has replaced one-third of its sales managers for its U.S. diabetes business in order to gain competitive advantages over Novo Nordisk.

By Nicole Gray • Feb. 10, 2015

Roche's blockbuster Lucentis nabs fourth FDA approval

Lucentis is now cleared for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

By Nicole Gray • Feb. 9, 2015

FDA warning for blockbuster hopeful edoxaban hits Daiichi where it hurts

Japanese drug maker Daiichi Sankyo is facing patent expiry on its top-selling drug, Benicar (olmesartan).

By Nicole Gray • Feb. 9, 2015

Arkansas settles Vertex Medicaid suit over pricey Kalydeco

The state will no longer require cystic fibrosis (CF) patients to use standard therapy for 12 months before becoming eligible for Kalydeco (ivacaftor), a $311,000-per-year drug.

By Nicole Gray • Feb. 9, 2015

Isis earns $10 million milestone from Biogen Idec

If ever there were a productive partnership, Biogen Idec and Isis Pharma have it.

By Nicole Gray • Feb. 6, 2015

Q4: Allergan soars past estimates, again

Allergan's 2014 revenues were up 14.7%.

By Nicole Gray • Feb. 6, 2015

Sanofi: Q4 earnings beat forecast, new CEO to be named by end of Q1 2015

A weak euro boosted the company's earnings. And it'll need to stay weak to ensure a good revenue haul for the year. 

By Sy Mukherjee • Feb. 5, 2015

Moody's: Patent-cliff challenges will continue to dog big pharma

According to Moody's, Pfizer, Eli Lilly, Merck, Amgen, and Novo Nordisk are more threatened now by patent losses than they were just a couple of years ago.

By Nicole Gray • Feb. 4, 2015

Merck's Belsomra for insomnia now available in US

Belsomra (suvorexant) is the first and only orexin receptor antagonist approved for the treatment of insomnia. 

By Nicole Gray • Feb. 4, 2015